

Sleep Disorders

Onabotulinum Toxin-A Injections for Nocturnal Bruxism: A Parallel, Double Blind, Placebo Controlled Polysomnographic Study (P05.006)

William Ondo¹, Vera Hashem², Christine Hunter³ and Jerry Simmons⁴

¹ Neurology University of Texas Health Science Center Houston TX ² Freelance Houston TX ³ Baylor College of Medicine Houston TX ⁴ Neurology Sadler Clinic Houston TX

Objective: To test the safety and efficacy of onabotulinum toxin-A injections into the masseter/temporalis muscles in patients with nocturnal bruxism.

Background Bruxism is probably the most common parasomnia, occurring in up to 15% of the population. There is no widely accepted treatment other than bite guards to limit dental damage.

Design/Methods: We performed a double blind, placebo injection controlled (1:1) trial of onabotulinum-A (BoNT) for nocturnal bruxism. Patients underwent a baseline/screening overnight polysomnogram (PSG). They were then randomized to receive BoNT or placebo into the bilateral masseter (60u/side) and temporalis muscles (40u/side) using visual landmarks. Primary efficacy points were CGI and VAS of change at 4 weeks post injection. Secondary points including change in PSG data, including masseter placed electrodes, pain scales, sleep scales, adverse events, and need for follow-up open label injection.

Results: Eight subjects were excluded after the initial PSG prior to randomization (six for lack of bruxism on PSG and two declined to continue). Twenty-three (19 female, age 47.4(16.9) were randomized. Almost all reported temporal-mandibular pain. All 13 randomized to drug and 9/10 randomized to placebo completed the study. CGI ($p < 0.05$) and VAS of change ($p < 0.05$) favored the BoNT group. Secondary scales including the Headache Impact Test-6, total Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and Self-Rated Anxiety Scale were not significantly changed. A large percentage of subjects had moderate obstructive sleep apnea on PSG despite lack of typical risk factors. The mean duration to open label f/u injection was 107 days in those randomized drug vs. 40 days in those randomized to placebo. Adverse events were limited to 2 subjects with a cosmetic change in their smile. No dysphagia was reported.

Conclusions: BoNT effectively and safely improved nocturnal bruxism in this small pilot trial. Multi-center confirmatory trials are justified.

Supported by: Unrestricted grant from Allergan.

Disclosure: Dr. Ondo has received personal compensation for activities with GlaxoSmithKline, Inc., Teva Neuroscience, Allergan, Inc., Merz Pharma, Ipsen, and Lundbeck Research USA, Inc. Dr. Ondo has received research support from GlaxoSmithKline, Inc., Bayer Healthcare, Takeda Pharmaceutical Company Limited, Teva Neuroscience, ACADIA, Parkinson Study Group and Huntington Study Group. Dr. Hashem has nothing to disclose. Dr. Hunter has received personal compensation for activities with Lundbeck Research USA, Inc. as a consultant. Dr. Simmons has received personal compensation for activities with Cephalon as a speaker.